News from the Children’s Oncology Group

Explore the latest news from across the Children’s Oncology Group, including advances in research, clinical trials, and care, alongside the stories behind this work.

Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children’s Oncology Group AALL0932

05/1/2021

Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia

04/6/2021

Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children’s Oncology Group

04/1/2021

Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group

04/1/2021

Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations

03/18/2021

Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial

03/2/2021

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

01/26/2021

Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia

01/14/2021

Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

01/1/2021